Angiogenesis is a key issue in the carcinogenesis progression. The development of anti-angiogenic targeted
therapies has made significant progress over the last decade. Targeting angiogenesis is considered as a part of the treatment
of metastatic colorectal cancer. Less data is available for the other gastrointestinal cancers. The objective of this article
is to provide a review of the angiogenesis targeting drugs evaluated in gastrointestinal non colorectal cancers. The review
is focused on the following 5 common gastrointestinal cancers: gastric, pancreatic, neuroendocrine cancers, biliary
cancers, and hepatocellular carcinoma.